Dubai-headquartered Kelix Bio, wholly owned by Abu Dhabi’s Mubadala Investment (Mubadala), has completed the acquisition of insulin manufacturer DiabTec, a subsidiary of Ras Al Khaimah-headquartered Julphar, for an undisclosed fee.
¬ Haymarket Media Limited. All rights reserved.